IL270069A - - Google Patents

Info

Publication number
IL270069A
IL270069A IL27006919A IL27006919A IL270069A IL 270069 A IL270069 A IL 270069A IL 27006919 A IL27006919 A IL 27006919A IL 27006919 A IL27006919 A IL 27006919A IL 270069 A IL270069 A IL 270069A
Authority
IL
Israel
Application number
IL27006919A
Other languages
English (en)
Other versions
IL270069B1 (en
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed filed Critical
Publication of IL270069A publication Critical patent/IL270069A/en
Publication of IL270069B1 publication Critical patent/IL270069B1/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55Protease inhibitors
    • A61K38/57Protease inhibitors from animals; from humans
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/81Protease inhibitors
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/81Protease inhibitors
    • C07K14/8107Endopeptidase (E.C. 3.4.21-99) inhibitors
    • C07K14/811Serine protease (E.C. 3.4.21) inhibitors
    • C07K14/8114Kunitz type inhibitors
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/38Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against protease inhibitors of peptide structure
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/543Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701Details
    • G01N2333/4703Regulators; Modulating activity
    • G01N2333/4704Inhibitors; Supressors
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00Detection or diagnosis of diseases
    • G01N2800/50Determining the risk of developing a disease
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00Detection or diagnosis of diseases
    • G01N2800/52Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00Detection or diagnosis of diseases
    • G01N2800/56Staging of a disease; Further complications associated with the disease
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00Detection or diagnosis of diseases
    • G01N2800/70Mechanisms involved in disease identification
    • G01N2800/7095Inflammation

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Cell Biology (AREA)
  • General Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Pathology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Zoology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
IL270069A 2017-04-25 2019-10-22 Methods for quantifying inter-alpha inhibitor proteins IL270069B1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762490003P 2017-04-25 2017-04-25
US201862614333P 2018-01-05 2018-01-05
PCT/US2018/029436 WO2018200722A1 (en) 2017-04-25 2018-04-25 Methods for quantifying inter-alpha inhibitor proteins

Publications (2)

Publication Number Publication Date
IL270069A true IL270069A (https=) 2019-12-31
IL270069B1 IL270069B1 (en) 2026-04-01

Family

ID=63920445

Family Applications (1)

Application Number Title Priority Date Filing Date
IL270069A IL270069B1 (en) 2017-04-25 2019-10-22 Methods for quantifying inter-alpha inhibitor proteins

Country Status (10)

Country Link
US (2) US20200057077A1 (https=)
EP (1) EP3615937B1 (https=)
JP (2) JP7293128B2 (https=)
KR (1) KR102587810B1 (https=)
CN (1) CN110691973B (https=)
AU (1) AU2018258466B2 (https=)
BR (1) BR112019022358A2 (https=)
CA (1) CA3061164A1 (https=)
IL (1) IL270069B1 (https=)
WO (1) WO2018200722A1 (https=)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018053029A1 (en) 2016-09-13 2018-03-22 Prothera Biologics, Inc. Methods for treating pulmonary disease using inter-alpha inhibitor proteins
BR112019022358A2 (pt) 2017-04-25 2020-05-19 Prothera Biologics, Inc. métodos para quantificar proteínas inibidoras inter-alfa
US20210393750A1 (en) * 2018-10-24 2021-12-23 Prothera Biologics, Inc. Inter-alpha inhibitor proteins and methods of use thereof
US20230416342A1 (en) 2020-11-16 2023-12-28 Prothera Biologics, Inc. Methods for purifying inter-alpha inhibitor proteins
US20230055086A1 (en) * 2021-08-19 2023-02-23 Prothera Biologics, Inc. Inter-alpha inhibitor proteins
CN114088949B (zh) * 2021-11-11 2024-09-27 王南 乌司他丁前体用于检测炎症的应用

Family Cites Families (64)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3854480A (en) 1969-04-01 1974-12-17 Alza Corp Drug-delivery system
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
US3832253A (en) 1973-03-21 1974-08-27 Baxter Laboratories Inc Method of making an inflatable balloon catheter
IE52535B1 (en) 1981-02-16 1987-12-09 Ici Plc Continuous release pharmaceutical compositions
US4667014A (en) 1983-03-07 1987-05-19 Syntex (U.S.A.) Inc. Nonapeptide and decapeptide analogs of LHRH, useful as LHRH antagonists
US4452775A (en) 1982-12-03 1984-06-05 Syntex (U.S.A.) Inc. Cholesterol matrix delivery system for sustained release of macromolecules
CA1200416A (en) 1983-05-13 1986-02-11 Societe Des Produits Nestle S.A. Food process
HUT35524A (en) 1983-08-02 1985-07-29 Hoechst Ag Process for preparing pharmaceutical compositions containing regulatory /regulative/ peptides providing for the retarded release of the active substance
US4839298A (en) 1986-02-14 1989-06-13 Akzo N.V. Virus inactivating diluents used in immunoassays
EP0367090B1 (en) 1988-11-01 1994-01-12 Schwarz Pharma Ag Lyophilized MDM composition and method of making it
GB8928501D0 (en) 1989-12-18 1990-02-21 Unilever Plc Reagents
JPH04167172A (ja) 1990-10-31 1992-06-15 Nec Corp ベクトルプロセッサ
US5166133A (en) 1991-04-17 1992-11-24 Cetus Corporation Method for inhibing adhesion of white blood cells to endothelial cells
FR2706466B1 (fr) 1993-06-14 1995-08-25 Aetsrn Concentré d'immunoglobulines G à usage thérapeutique et procédé de production dudit concentré.
FR2711371B1 (fr) 1993-10-18 1995-12-29 Aetsrn Procédé de préparation d'un concentré d'inter-alpha-trypsine inhibiteur à usage thérapeutique et concentré obtenu.
US6313091B1 (en) 1995-07-20 2001-11-06 New York University Pharmaceutical compositions containing TSG-6 for treating inflammatory diseases and cancer-related pathologies and method
JP4217717B2 (ja) * 1996-07-16 2009-02-04 生化学工業株式会社 血清由来ヒアルロナン結合性タンパク質−ヒアルロン酸結合体の測定法および測定キット
AU5134799A (en) 1998-07-30 2000-02-21 Human Genome Sciences, Inc. 98 human secreted proteins
US6673908B1 (en) 1999-02-22 2004-01-06 Nuvelo, Inc. Tumor necrosis factor receptor 2
US6489128B1 (en) 2000-01-24 2002-12-03 Rhode Island Hospital, A Lifespan Partner Methods for detecting cancer of the central nervous system
US6660482B1 (en) 2000-02-28 2003-12-09 Rhode Island Hospital Inter-alpha-trypsin inhibitor as a marker for sepsis
EP1326893A2 (de) 2000-10-13 2003-07-16 Octapharma AG Bikunin enthaltende plasmafraktion, verfahren zu ihrer herstellung und ihrer verwendung
AU2002224408B2 (en) 2000-10-18 2007-08-23 Massachusetts Institute Of Technology Methods and products related to pulmonary delivery of polysaccharides
DE60120500T2 (de) 2000-12-08 2007-06-06 Genentech, Inc., South San Francisco In Knorpelgeweben stark exprimiertes Gen
GB0114709D0 (en) 2001-06-15 2001-08-08 Pfizer Ltd Stabilised formulations of amlodipine maleate
US20030027848A1 (en) 2001-06-15 2003-02-06 Anne Billotte Stabilized formulations
US20040009212A1 (en) 2002-01-30 2004-01-15 Pharma Power Biotec Co. Ltd. Mucoadhesive thermoresponsive medicament-carrier composition
DE10204462A1 (de) 2002-02-05 2003-08-07 Boehringer Ingelheim Pharma Verwendung von Tyrosinkinase-Inhibitoren zur Behandlung inflammatorischer Prozesse
AU2003226021B2 (en) 2002-03-26 2008-07-17 Teva Pharmaceutical Industries Ltd. Drug microparticles
JP4180911B2 (ja) 2002-12-27 2008-11-12 生化学工業株式会社 新規酵素活性測定方法
WO2004082615A2 (en) 2003-03-14 2004-09-30 Nirmal Mulye A process for preparing sustained release tablets
CN1160123C (zh) 2003-05-26 2004-08-04 广东天普生化医药股份有限公司 乌司他丁用于治疗严重急性呼吸综合征的用途及其药物组合物
WO2005030252A1 (en) 2003-09-23 2005-04-07 Pdl Biopharma, Inc. Treatment of respiratory diseases with anti-il-2 receptor antibodies
EP3087991A1 (en) 2003-11-08 2016-11-02 Prothera Biologics Composition of inter-alpha inhibitor proteins from human plasma for therapeutic use
EP3127916A1 (en) 2004-06-07 2017-02-08 Therapure Biopharma Inc. Isolation of plasma or serum proteins
US7939282B2 (en) * 2004-10-21 2011-05-10 Rhode Island Hospital Methods for detecting sepsis
CN101160133B (zh) 2004-11-05 2013-01-09 普罗瑟拉生物公司 治疗用途的来自人血浆的内-α抑制剂蛋白质的制备和组合物
CN103142650B (zh) 2004-11-05 2016-05-11 普罗瑟拉生物公司 治疗用途的来自人血浆的内-α抑制剂蛋白质的制备和组合物
US8182840B2 (en) 2005-09-27 2012-05-22 Tissue Tech, Inc. Amniotic membrane preparations and purified compositions and therapy for scar reversal and inhibition
BRPI0620316A2 (pt) 2005-12-21 2011-11-08 Wyeth Corp formulações de proteìnas com viscosidades reduzida e seus usos
WO2008067655A1 (en) 2006-12-05 2008-06-12 Q6 Biomaterials Inc. Biocompatible hydrogel-based scaffolds
US8026345B2 (en) 2007-01-08 2011-09-27 Hoffmann-La Roche Inc. Characterization and identification of unique human adiponectin isoforms and antibodies
KR100846354B1 (ko) 2007-03-21 2008-07-15 (주) 프로탄바이오 혈청 당단백질부터 분리한 폐암 진단용 마커
WO2009020481A2 (en) 2007-05-08 2009-02-12 Rq Bioscience, Inc. Therapeutic compositions and methods for treating gram-negative bacterial infections
CN106928346B (zh) * 2008-05-28 2021-09-07 普罗瑟拉生物公司 来自血液的间-α抑制物蛋白的制备和组合物
HRP20160760T1 (hr) 2008-07-18 2016-08-12 A1M Pharma Ab Medicinska uporaba čistača radikala i antioksidacijskog alfa-1-mikroglobulina
US20110236381A1 (en) 2008-12-10 2011-09-29 Stavros Garantziotis Inhibition of inter-alpha trypsin inhibitor for the treatment of airway disease
WO2011150284A2 (en) 2010-05-26 2011-12-01 Baxter International Inc. Removal of serine proteases by treatment with finely divided silicon dioxide
WO2011150944A1 (en) 2010-06-04 2011-12-08 Trifoilium Aps Trefoil factors (tff) for the treatment of chronic pulmonary diseases
US9562906B2 (en) 2010-06-10 2017-02-07 National University Of Singapore Methods for detection of gastric cancer
SG187599A1 (en) 2010-07-23 2013-03-28 Baxter Int Manufacture of inter -alpha - inhibitor proteins (iaip) from plasma
WO2012119065A2 (en) 2011-03-03 2012-09-07 Seachaid Pharmaceuticals, Inc. Antifungal agents and uses thereof
JP2013101047A (ja) 2011-11-08 2013-05-23 Nagasaki Univ 14−3−3蛋白γアイソフォーム特異的ELISA
SI3677252T1 (sl) 2012-03-19 2024-02-29 Cidara Therapeutics, Inc. Sheme odmerjanja za spojine iz razreda ehinokandinov
ES2846789T3 (es) 2012-07-11 2021-07-29 Tissuetech Inc Composiciones que contienen complejos HC-HA/PTX3 y métodos de uso de los mismos
WO2014039987A2 (en) 2012-09-09 2014-03-13 Prothera Biologics, Inc. Treatment of disease using inter-alpha inhibitor proteins
US20140206844A1 (en) 2013-01-18 2014-07-24 Prothera Biologics Methods for isolating blood products from an inter-alpha inhibitor protein-depleted blood product material
WO2015071402A1 (en) 2013-11-15 2015-05-21 Nestec S.A. Compositions for use in the prevention or treatment of necrotizing enterocolitis in infants and young children
JP6183174B2 (ja) 2013-11-26 2017-08-23 ユーハ味覚糖株式会社 ヒアルロン酸高含有固形食品及びその製造方法
WO2016138476A1 (en) 2015-02-26 2016-09-01 Mycotechnology, Inc. Methods for lowering gluten content using fungal cultures
WO2018053029A1 (en) 2016-09-13 2018-03-22 Prothera Biologics, Inc. Methods for treating pulmonary disease using inter-alpha inhibitor proteins
BR112019022358A2 (pt) 2017-04-25 2020-05-19 Prothera Biologics, Inc. métodos para quantificar proteínas inibidoras inter-alfa
US20210393750A1 (en) 2018-10-24 2021-12-23 Prothera Biologics, Inc. Inter-alpha inhibitor proteins and methods of use thereof
US20230416342A1 (en) 2020-11-16 2023-12-28 Prothera Biologics, Inc. Methods for purifying inter-alpha inhibitor proteins

Also Published As

Publication number Publication date
AU2018258466A1 (en) 2019-12-05
EP3615937B1 (en) 2026-01-28
KR102587810B1 (ko) 2023-10-11
JP2023085249A (ja) 2023-06-20
KR20200010262A (ko) 2020-01-30
CA3061164A1 (en) 2018-11-01
JP2020517967A (ja) 2020-06-18
EP3615937A4 (en) 2021-08-11
US20200057077A1 (en) 2020-02-20
WO2018200722A1 (en) 2018-11-01
EP3615937C0 (en) 2026-01-28
AU2018258466B2 (en) 2025-05-22
CN110691973B (zh) 2024-11-29
EP3615937A1 (en) 2020-03-04
US12265090B2 (en) 2025-04-01
JP7293128B2 (ja) 2023-06-19
BR112019022358A2 (pt) 2020-05-19
US20220099684A1 (en) 2022-03-31
CN110691973A (zh) 2020-01-14
IL270069B1 (en) 2026-04-01

Similar Documents

Publication Publication Date Title
BR122021024395A2 (https=)
BR112019008823A2 (https=)
BR112020006084A8 (https=)
IL270069A (https=)
BR122022025811B8 (https=)
BR122021023687A2 (https=)
BR122021014832A2 (https=)
BR122022003521A2 (https=)
BR112020008820A2 (https=)
BR102017023327A2 (https=)
BR202017021228U2 (https=)
BE2017C035I2 (https=)
BR102017015495A2 (https=)
BR102017015250A2 (https=)
BR102017014430A2 (https=)
BR202017010373U2 (https=)
BR202017009870U2 (https=)
BR202017006953U2 (https=)
BR202017004898U2 (https=)
BR102017003115A2 (https=)
BR202017002937U2 (https=)
BR202017002826U2 (https=)
CN303997434S (https=)
CN303997205S (https=)
CN303997564S (https=)